Anlotinib (??? (Fukewi), AL3818)
Targeted Therapy
Description
Anlotinib is a multi-target tyrosine kinase inhibitor that demonstrates activity in metastatic colorectal cancer as monotherapy and in combination with immunotherapy agents. This oral targeted therapy has shown particular promise in patients with non-liver metastatic disease and as second-line treatment options. Clinical data supports its use both as first-line therapy combined with sintilimab and in second-line settings with irinotecan-based regimens.
Mechanism of Action
Anlotinib functions as a multi-kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor angiogenesis and growth signaling pathways. The drug primarily targets VEGFR1, VEGFR2, VEGFR3, FGFR1-4, PDGFR- / , and c-Kit, thereby inhibiting both tumor vascularization and direct tumor cell proliferation signals.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | ??? (Fukewi), AL3818 |
| Category | Targeted Therapy |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 4 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.